MOLN

Molecular Partners AG

Phase 1 AI-extracted

MP0317

advanced cancer types

Resolved

918days ago

Phase 1 readout · Jan 1, 2024

What's at stake Phase 1 trial results for MP0317 in advanced cancer types are due Jan 1, 2024. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 13h ago

“Data were presented at the 2024 Annual Meetings of the American Society of Clinical Oncology (ASCO) and of the Society for Immunotherapy of Cancer (SITC).”

Add to calendar Post on X Reddit

Provenance